IGHE and allergic asthma: Omalizumab is the only approved anti-IgE monoclonal antibody in patients aged ≥6 years with uncontrolled moderate-to-severe (United States) and severe (European Union) allergic asthma as an add-on to standard-of-care treatment with high-dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA).38